Activation microgliale dans la Narcolepsie de type 1: medical imaging study
- Conditions
- To study in vivo microglial activation by PET [18F] DPA-714 in NT1 patients with recent evolution (appearance of the first symptoms - somnolence and cataplexy-less than 2 years ago) compared with controlled subjects (followed for another pathology of sleep without narcolepsy or hypersomnia) matched in age and sex.Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2018-001584-23-FR
- Lead Sponsor
- niversity Hospital of Montpellier
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 30
Narcoleptic patients Inclusion Criteria :
- Clinical diagnosis of NT1 according to International Classification of Sleep Disorders, 3rd Edition (AASM: American Academy of Sleep Medicine, 2014), with beginning of symptoma since 2 years top (somnolence and/or cataplexy)
- With or without psychostimulant treatment for the pathology
Control patients Inclusion Criteria :
- Sleep disorder without objectification of narcolepsy or hypersomnia and without any inflammatory pathology.
Non-specific Inclusion Criteria :
- Age over 18
- Absence of contraindication to the performance of PET [18F] DPA-714
- Absence of immunomodulatory or anti-inflammatory treatment
- Subjects having given their written and informed consent for this study
- Subjects speaking and including French
- Affiliated to social security
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5
Exclusion Criteria (non-specific patients/control) :
- Refusal to perform PET Imaging in [18F] DPA-714
- Pregnant or lactating women
- Subject deprived of liberty, by judicial or administrative decision
- Major protected by law
- Subject without social security
- Subject in exclusion period after another protocol
- Refusal to participate in the protocol
- Contraindications to MRI
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method